Institute of Personalized Medicine - PUMA IPM
Pharmacogenomics aims at understanding how variations in the human genome affect the response to medications.
Our researchers are working to generate new knowledge, and to develop tools and algorithms that can help in personalizing medicine utilizing a patient’s genetic profile and other factors to achieve maximum therapeutic benefit with minimum toxicity.
Pamala Jacobson received the Sara Evans Faculty Woman Scholar/ Leader Award from the University of Minnesota Women’s Center, Office for Equity and Diversity and was honored at their Celebrating Changemakers Awards event on October 11, 2018.
This session highlighted the social and cultural challenges associated with providing care to local Native American tribes in Minnesota, who face larger health disparities than other populations.
David Stenehjem works in the rapidly growing field of outcomes research, which guides his research on midostaurin in FLT3-mutated acute myeloid leukemia.
Samuel is a PhD Candidate in the Experimental and Clinical Pharmacology department. During his time in the program Samuel has pursued various avenues of research related to precision medicine in neuropharmacology with a focus on anti-seizure drugs.
Precision Medicine Seminar Series
"Precision Medicine in Mental Health: Challenges and Opportunities for Pharmacogenomics"
Presented by Jeffrey R. Bishop, PharmD, MS, BCPP
Associate Professor of Experimental & Clinical Pharmacology, University of Minnesota
Genomic Testing to Individualize Drug Therapy
The 2018 Pharmacogenomics Conference on June 22 was at capacity with over 310 registrants in attendance. Topics included: cancer somatic mutations and selection of targeted therapies, emerging PGx areas. Read about the event here.
University Precision Medicine Initiatives
Bringing together scientists, healthcare providers, patients and payers in the area of precision medicine to promote research, education and the use of precision medicine and health to improve human health.
Transforming health and advancing equity by generating precision treatments of disease to advance health outcomes for all Minnesotans.